Biomedical Engineering Reference
In-Depth Information
for directed prodrug therapies. Curr. Med. Chem. 15(16),
1606-1615.
64. Guicciardi ME, Gores GJ. (2009) Life and death by death
receptors. FASEB J. 23(6), 1625-1637.
65. Krippner-Heidenreich A, Grunwald I, Zimmermann G,
Kuhnle M, Gerspach J, Sterns T, et al. (2008) Single-chain
TNF, a TNF derivative with enhanced stability and anti-
tumoral activity. J. Immunol. 180(12), 8176-8183.
66. Bauer S, Adrian N, Fischer E, Kleber S, Stenner F, Wadle A,
et al. (2006) Structure-activity profiles of Ab-derived TNF
fusion proteins. J. Immunol. 177(4), 2423-2430.
67. Gerspach J, Pfizenmaier K, Wajant H. (2009) Improving TNF
as a cancer therapeutic: tailor-made TNF fusion proteins with
conserved antitumor activity and reduced systemic side
effects. Biofactors 35(4), 364-372.
68. Holler N, Tardivel A, Kovacsovics-Bankowski M, Hertig S,
Gaide O, Martinon F, et al. (2003) Two adjacent trimeric Fas
ligands are required for Fas signaling and formation of a
death-inducing signaling complex. Mol. Cell. Biol. 23(4),
1428-1440.
69. Eisele G, Roth P, Hasenbach K, Aulwurm S, Wolpert F,
Tabatabai G, et al. (2011) APO010, a synthetic hexameric
CD95 ligand, induces human glioma cell death in vitro and
in vivo. Neuro-oncol. 13(2), 155-164.
70. Bremer E, ten Cate B, Samplonius DF, Mueller N, Wajant H,
Stel AJ, et al. (2008) Superior activity of fusion protein
scFvRit: sFasL over cotreatment with rituximab and Fas
agonists. Cancer Res. 68(2), 597-604.
71. Watermann I, Gerspach J, Lehne M, Seufert J, Schneider B,
Pfizenmaier K, et al. (2007) Activation of CD95L fusion
protein prodrugs by tumor-associated proteases. Cell Death
Differ. 14(4), 765-774.
72. Liu Z, Wang J, Yin P, Qiu J, Liu R, Li W, et al. (2009) RGD-
FasL induces apoptosis in hepatocellular carcinoma. Cell.
Mol. Immunol. 6(4), 285-293.
73. Schneider B, Munkel S, Krippner-Heidenreich A, Grunwald
I, Wels WS, Wajant H, et al. (2010) Potent antitumoral
activity of TRAIL through generation of tumor-targeted
single-chain fusion proteins. Cell Death Dis. 1, e68.
74. Cao L, Du P, Jiang S-H, Jin G-H, Huang Q-L, Hua Z-C.
(2008) Enhancement of antitumor properties of TRAIL by
targeted delivery to the tumor neovasculature. Mol. Cancer
Ther. 7(4), 851-861.
75. Bremer E, Samplonius DF, van Genne L, Dijkstra MH,
Kroesen BJ, de Leij LFMH, et al. (2005) Simultaneous
inhibition of epidermal growth factor receptor (EGFR)
signaling and enhanced activation of tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL) receptor-
mediated apoptosis induction by an scFv:sTRAIL fusion
protein with specificity for human EGFR. J. Biol. Chem.
280(11), 10025-10033.
76. Aqeilan R, Kedar R, Ben-Yehudah A, Lorberboum-Galski
H. (2003) Mechanism of action of interleukin-2 (IL-2)-Bax,
an apoptosis-inducing chimaeric protein targeted against
cells expressing the IL-2 receptor. Biochem. J. 370(Pt 1),
129-140.
77. Azar Y, Lorberboum-Galski H. (2000) GnRH-Bik/Bax/Bak
chimeric proteins target and kill adenocarcinoma cells; the
general use of pro-apoptotic proteins of the Bcl-2 family as
novel killing components of targeting chimeric proteins.
Apoptosis 5(6), 531-542.
78. Qiu X-C, Xu Y-M, Wang F, Fan Q-Y, Wang L-F, Ma B-A,
et al. (2008) Single-chain antibody/activated BID chimeric
protein effectively suppresses HER2-positive tumor growth.
Mol. Cancer Ther. 7(7), 1890-1899.
79. Shan L-Q, Ma S, Qiu X-C, Wang T, Yu S-B, Ma B-A, et al.
(2011) A novel recombinant immuno-tBid with a furin site
effectively suppresses the growth of HER2-positive osteo-
sarcoma cells in vitro. Oncol. Rep. 25(2), 325-331.
80. Weisbart RH, Hansen JE, Chan G, Wakelin R, Chang SS,
Heinze E, et al. (2004) Antibody-mediated transduction
of p53 selectively kills cancer cells. Int. J. Oncol. 25(6),
1867-1873.
81. Hansen JE, Fischer LK, Chan G, Chang SS, Baldwin SW,
Aragon RJ, et al. (2007) Antibody-mediated p53 protein
therapy prevents liver metastasis in vivo. Cancer Res.
67(4), 1769-1774.
82. Correale P, Cusi MG, Tagliaferri P. (2011) Immunomodula-
tory properties of anticancer monoclonal antibodies: is the
“magic bullet” still a reliable paradigm? Immunotherapy
3(1), 1-4.
83. Taylor L, Bachler M, Duncan I, Keen S, Fallon R, Mair C, et
al. (2002) In vitro and in vivo activities of OX40 (CD134)-IgG
fusion protein isoforms with different levels of immune-
effector functions. J. Leukoc. Biol. 72(3), 522-529.
84. Desjarlais JR, Lazar GA. (2011) Modulation of antibody
effector function. Exp. Cell Res. 317(9), 1278-1285.
85. Topham NJ, Hewitt EW. (2009) Natural killer cell cyto-
toxicity: how do they pull the trigger? Immunology 128(1),
7-15.
86. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, et al.
(2006) Engineered antibody Fc variants with enhanced effec-
tor function. Proc. Natl. Acad. Sci. U S A 103(11), 4005-
4010.
87. Masuda K, Kubota T, Kaneko E, Iida S, Wakitani M,
Kobayashi-Natsume Y, et al. (2007) Enhanced binding affin-
ity for FcgammaRIIIa of fucose-negative antibody is
sufficient to induce maximal antibody-dependent cellular
cytotoxicity. Mol. Immunol. 44(12), 3122-3131.
88. Repp R, Kellner C, Muskulus A, Staudinger M, Nodehi SM,
Glorius P, et al. (2011) Combined Fc-protein- and Fc-glyco-
engineering of scFv-Fc fusion proteins synergistically enhan-
ces CD16a binding but does not further enhance NK-cell
mediated ADCC. J. Immunol. Methods 373(1-2), 67-78.
89. Nagashima H, Kaneko K, Yamanoi A, Motoi S, Konakahara
S, Kohroki J, et al. (2011) TNF receptor II fusion protein with
tandemly repeated Fc domains. J. Biochem. 149(3), 337-346.
90. Shoji-Hosaka E, Kobayashi Y, Wakitani M, Uchida K, Niwa
R, Nakamura K, et al. (2006) Enhanced Fc-dependent
cellular cytotoxicity of Fc fusion proteins derived from
TNF receptor II and LFA-3 by fucose removal from Asn-
linked oligosaccharides. J. Biochem. 140(6), 777-783.
Search WWH ::
Custom Search